| EPB248 | High levels of non-nucleoside reverse transcriptase inhibitor (NNRTI) pre-treatment HIV drug resistance (PDR) in Zambia: results from the national survey | E-poster | Resistance to ART |
| EPB247 | Evaluation of HIV drug resistance in virally suppressed patients in Cameroon | E-poster | Resistance to ART |
| EPB246 | High-level of cross-resistance to 2nd generation non-nucleoside reverse transcriptase inhibitors among patients failing antiretroviral therapy in Cameroon: implications for future ART-regimens in Africa | E-poster | Resistance to ART |
| EPB245 | High drug resistance levels compromise the control of HIV infection in paediatric and adult populations in Bata, Equatorial Guinea | E-poster | Resistance to ART |
| EPB244 | Drug resistance in children with HIV in the Democratic Republic of Congo, Equatorial Guinea and Panama | E-poster | Resistance to ART |
| EPB243 | Frequency of virologic factors possibly associated with CAB/RPV LAI failure | E-poster | Resistance to ART |
| EPB242 | HIV genotypic drug resistance testing outcomes using Dry Blood Spot samples from patients failing second-line antiretroviral therapy and attending routine care in 3 rural districts of Zimbabwe | E-poster | Resistance to ART |
| EPB241 | Minimal acquired resistance to dolutegravir and bictegravir in patients failing third-line ART in South Africa | E-poster | Resistance to ART |
| EPB240 | Resistance analysis of long-acting Lenacapavir in highly treatment-experienced people with HIV after 52 weeks of treatment | E-poster | Resistance to ART |
| EPB239 | Resistance analysis of long-acting lenacapavir in treatment-naïve people with HIV at 54 weeks | E-poster | Resistance to ART |